While the proportion of patients with early HCC (i.e., very early and early stage HCC based on the BCLC classification) was highest in the AFP group (83.2% vs. 67.6%, P<0.001), more advanced tumors were most frequent in the AFP+US group. This evidence concerns the gene AFP and hepatocellular carcinoma.